Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Loke

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Frontiers in Immunology|May 20, 2021
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?Justin Loke, Richard Buka, Charles Craddock
Frontiers in Oncology|May 3, 2021
Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid LeukemiaJustin Loke, Hrushikesh Vyas, Charles Craddock
British Journal of Haematology|December 12, 2019
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experienceJustin Loke, Ram Malladi, Paul Moss, et al.
British Journal of Haematology|April 11, 2024
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemiaFrancesca A M Kinsella, Maria A L Maroto, Justin Loke, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 23, 2007
Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patientsDavid Hughes, John Hafferty, Lee Fulton, et al.
Blood Advances|February 13, 2018
C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemiaJustin Loke, Paulynn Suyin Chin, Peter Keane, et al.
British Journal of Haematology|September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapyJustin Loke, Marlen Metzner, Rebecca Boucher, et al.
British Journal of Haematology|September 10, 2025
UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)Andrew Clark, Hazel Clouston, Kanchan Rao, et al.
Cell Reports|May 25, 2017
RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AMLJustin Loke, Salam A Assi, Maria Rosaria Imperato, et al.
Blood|February 25, 2015
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic targetFrancis Mussai, Sharon Egan, Joseph Higginbotham-Jones, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|May 20, 2021
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?Justin Loke, Richard Buka, Charles Craddock
Frontiers in Oncology|May 3, 2021
Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid LeukemiaJustin Loke, Hrushikesh Vyas, Charles Craddock
British Journal of Haematology|December 12, 2019
The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experienceJustin Loke, Ram Malladi, Paul Moss, et al.
British Journal of Haematology|April 11, 2024
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemiaFrancesca A M Kinsella, Maria A L Maroto, Justin Loke, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|November 23, 2007
Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patientsDavid Hughes, John Hafferty, Lee Fulton, et al.
Blood Advances|February 13, 2018
C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemiaJustin Loke, Paulynn Suyin Chin, Peter Keane, et al.
British Journal of Haematology|September 7, 2021
Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapyJustin Loke, Marlen Metzner, Rebecca Boucher, et al.
British Journal of Haematology|September 10, 2025
UK recommendations for chimerism testing and monitoring following allogeneic haematopoietic stem cell transplantation (HSCT): Best practice consensus guidelines from the British Society for Blood and Marrow Transplant and Cellular Therapies (BSBMTCT), NHS England Genomic Laboratory Hub (GLH) Haematological Malignancies Working Group, UK Cancer Genetics Group (UKCGG) and the UK National External Quality Assessment Service for Leucocyte Immunophenotyping (UK NEQAS LI)Andrew Clark, Hazel Clouston, Kanchan Rao, et al.
Cell Reports|May 25, 2017
RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AMLJustin Loke, Salam A Assi, Maria Rosaria Imperato, et al.
Blood|February 25, 2015
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic targetFrancis Mussai, Sharon Egan, Joseph Higginbotham-Jones, et al.
Pageof 3